Recent research are creating significant attention surrounding Novo Nordisk's new drug , a innovative dual agonist targeting incretin and glucose-dependent insulinotropic polypeptide. Distinct from existing slimming medications , retatrutide seems to offer substantial reductions in abdominal circumference and enhance insulin health in early assess